Why did INBS miss Q4 2024 earnings forecasts?

Intelligent Bio Solutions (INBS) did not provide earnings forecasts for Q4 2024 in its financial reports. However, we can infer that the company's financial performance in Q4 2024 was likely impacted by several strategic initiatives and operational developments:

1. **Strategic Partnerships**: INBS partnered with B2i Digital for investor relations and marketing campaigns, which could have allocated resources and impacted financials.
2. **FDA 510(k) Submission**: The company was actively preparing for FDA 510(k) clearance of its Intelligent Fingerprinting Drug Screening technology, which might have been a significant focus, potentially affecting financial outcomes.
3. **Revenue Growth**: Despite the challenges, INBS showed revenue growth, with a 10% year-on-year increase and 20% quarter-on-quarter rise, marking four consecutive quarters of year-on-year growth. This was driven by expansion into new regions and an increase in customer base, leading to higher revenue and lower costs.

In summary, INBS's Q4 2024 financial performance was likely a result of strategic initiatives, FDA 510(k) preparations, and revenue growth, rather than missing earnings forecasts.